// App-Quantinova.ai

EP599 : IMPACT OF UNFAVORABLE GENETICS ON MINIMAL RESIDUAL DISEASE (MRD) RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

Researchers

Presenter

  • Jenny Qun Wu

Principal Investigators

  • John F. Seymour

  • Barbara Eichhorst

  • Peter Hillmen

  • Thomas Kipps

  • Anton W. Langerak

  • Carolyn Owen

  • Julie Dubois

  • Clemens Mellink

  • Anne-Marie van der Kevie-Kersemaekers

  • Brenda Chyla

  • Yanwen Jiang

  • Michelle Boyer

  • Maria Thadani Mulero

  • Marcus Lefebure

  • Arnon P. Kater

Medical Centers

  • University of Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, Cologne, Germany

  • AbbVie, N Chicago, United States

  • UCSD Moores Cancer Center,San Diego,United States

  • Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne,Melbourne,Australia

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • St. James's University Hospital, Leeds, United Kingdom

  • Genentech Inc., San Francisco, United States

  • Univ of Calgary, Calgary, Canada

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Dept of Hematology and Lymphoma and Myeloma Center Amsterdam (LYMMCARE),Amsterdam University Medical Centers, University of Amsterdam,Amsterdam,Netherlands

  • German CLL Study Group, Cologne, Germany,Cologne,Germany

Locations

  • Germany

  • United States

  • Australia

  • Netherlands

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved